Quiz

Incidence of PIK3CA Mutations in Breast Cancer

09/25/2024

Recent News

News

FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer

10/17/2024

On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.

On October 15, 2024, the FDA...

10/17/2024

Oncology

News

Treatment With 131L-Apamistamab Before AlloHCT Demonstrates Efficacy, Safety Among Older Patients With R/R AML

10/15/2024

Amber Denham ;

According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...

According to phase 3 results...

10/15/2024

Oncology

FDA Approval

FDA Approves Inavolisib, With Palbociclib and Fulvestrant, for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer

10/10/2024

Allison Casey ;

The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.

The FDA has approved inavolisib,...

10/10/2024

Oncology

News

Momelotinib Demonstrates Improved Spleen and Symptom Requirements Among Subgroup of Patients With JAK Inhibitor-Naive Myelofibrosis

10/10/2024

Amber Denham ;

Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.

Momelotinib was well-tolerated,...

10/10/2024

Oncology

News

Nivolumab, Pomalidomide, and Elotuzumab Combination for Patients With R/R Multiple Myeloma

10/10/2024

Amber Denham ;

Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...

Nivolumab plus pomalidomide and...

10/10/2024

Oncology

News

Evaluating Long-Term Efficacy and Safety of AlloSCT Among Patients With Peripheral T-Cell Lymphoma

10/10/2024

Amber Denham ;

While allogeneic stem cell transplantation is the preferred treatment for younger, transplant-eligible patients with relapsed/refractory peripheral T-cell lymphoma, it is currently not recommended as part of first-line consolidation,...

While allogeneic stem cell...

10/10/2024

Oncology

News

Neo/Adjuvant Pembrolizumab Significantly Improves Overall Survival for Patients With Early-Stage Triple-Negative Breast Cancer

10/09/2024

Stephanie Holland ;

According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.

According to results from the...

10/09/2024

Oncology

Conference Coverage

Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer

10/09/2024

Stephanie Holland ;

According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.

According to interim analysis...

10/09/2024

Oncology

News

Encorafenib Plus Binimetinib for BRAF V600E-Mutant Advanced Non-Small Cell Lung Cancer in the First-Line Setting

10/08/2024

Allison Casey ;

According to phase 2 results, encorafenib plus binimetinib showed clinical activity for BRAF V600E-mutant advanced non-small cell lung cancer in the first-line setting.

According to phase 2 results,...

10/08/2024

Oncology

FDA Approval

FDA Approves Multitarget Stool DNA Test for Patients at Average Risk for Colorectal Cancer

10/07/2024

Stephanie Holland ;

Based on results from the BLUE-C study, the FDA has approved the Cologuard Plus™ test for patients 45 years and older at average risk for colorectal cancer.

Based on results from the BLUE-C...

10/07/2024

Oncology